Skip to content

Transcranial Direct Current Stimulation for Migraine Attack

Manho Kim, MD, PhD Professor, Neurology Seoul National University Hospital,

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01358279
Enrollment
32
Registered
2011-05-23
Start date
2009-01-31
Completion date
2011-03-31
Last updated
2016-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Migraine

Brief summary

This study is conducted to investigate the therapeutic efficacy and safety of transcranial direct current stimulation (tDCS) over the primary motor cortex of patients with acute migraine attack.

Interventions

PROCEDUREtranscranial direct current stimulation

A constant current of 2 mA intensity applied for 20 min over C3 or C4

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
17 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Aged 17-70 years * Migraine * With or without aura * The first attack of migraine was earlier than 50 years of age * One to 8 moderate to severe migraine attacks per month in the 2 months preceding the screening * Willing and able to give written informed consent * Able to read, comprehend and complete the diary form

Exclusion criteria

* Not able to distinguish between migraine and non-migraine headache * Combined headache, including the tension type headache and medication overuse headache * Pregnant, actively trying to become pregnant or breast-feeding women * Uncontrolled and significant medical illness * Vertebrobasilar or hemiplegic migraine according to the International Headache Society diagnostic criteria * Having intracranial metal implants or a cardiac pacemaker * A history of epilepsy or other organic brain disorders * A history of psychological diseases * Having changed medications for migraine within 1 month before giving us informed consent * Drug abuser or alcoholics

Design outcomes

Primary

MeasureTime frame
Number of participants who experienced pain relief of one level or moreat 2h post-treatment

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026